Formycon Seeks Prime Standard Listing on Frankfurt Stock Exchange

Formycon AG has announced its application for admission to the Prime Standard of the Frankfurt Stock Exchange. The decision aims at increasing international investor visibility and share liquidity. The company's shares are set to begin trading in this segment on November 12, 2024, following expected approvals. This move could lead to Formycon's inclusion in select Deutsche Börse indices, enhancing stock appeal further.

Recently included in the MSCI Germany Small Cap Index, Formycon is committed to meeting rigorous transparency standards demanded by the Prime Standard. Currently, the shares are traded on the open market's Scale segment but will transition with the same ISIN and WKN.

Formycon specializes in biosimilars, already marketing products like FYB201 across Europe and the USA. The uplisting supports its strategic growth and international market repute.